Thromb Haemost 1986; 55(01): 019-023
DOI: 10.1055/s-0038-1661438
Original Article
Schattauer GmbH Stuttgart

Heparin Cofactor II: Purification and Antibody Production

Tri H Tran
The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basel, Switzerland
,
B Lämmle
The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basel, Switzerland
,
B Zbinden
The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basel, Switzerland
,
F Duckert
The Coagulation and Fibrinolysis Laboratory, Kantonsspital, Basel, Switzerland
› Author Affiliations
Further Information

Publication History

Received 08 July 1985

Accepted 09 October 1985

Publication Date:
19 July 2018 (online)

Heparin cofactor II (HCII) was purified from plasma to homogeneity. The procedure includes adsorption with (Al)OH3, fractionation with polyethylene glycol 6000, chromatography on QAE-Sephadex A-50, on heparin-Sepharose 4B and on Sephadex G-150. QAE-Sephadex A-50 chromatography provides a good separation of HCII from antithrombin III (AT) and most contaminants having a heparin affinity similar to that of HCII. HCII is eluted at 0.28 M NaCl from the heparin-Sepharose column. After gel filtration on G-150, contaminating AT was removed by immunoadsorption. Purified HCII shows an apparent Mr of 66,500 dal tons as analyzed on SDS-polyacrylamide gel and 62,100 daltons by ultracentrifugation. Antibodies to HCII were raised in rabbits. Former antisera mostly directed to a contaminating protein were used to remove it from the HCII preparation. Antibodies to HCII were made monospecific by immunoadsorption on HCII-free plasma linked to Sepharose 4B. Since many functional AT assays have neglected the presence of HCII in plasma, antibodies to HCII using as immunoadsorbent will provide a more specific test for AT.

 
  • References

  • 1 Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand J Lab Invest 1968; 21: 89-91
  • 2 Yin ET, Wessler S, Stoll PJ. Identity of plasma-activated factor X inhibitor with antithrombin III and heparin cofactor. J Biol Chem 1971; 246: 3712-3719
  • 3 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin - heparin cofactor. J Biol Chem 1973; 248: 6490-6505
  • 4 Briginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma: I Separation and partial purification. Arch Biochem Biophys 1974; 161: 683-690
  • 5 Briginshaw GF, Shanberge JN. Identification of two distinct heparin cofactors in human plasma: II Inhibition of thrombin and activated factor X. Thromb Res 1974; 4: 463-477
  • 6 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
  • 7 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
  • 8 Wunderwald P, Schrenk WJ, Port H. Antithrombin BM from human plasma: an antithrombin binding moderately to heparin. Thromb Res 1982; 25: 177-199
  • 9 Cuatrecasas P. Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads. J Biol Chem 1970; 245: 3059-3065
  • 10 Tran TH, Bounameaux H, Bondeli C, Honkanen H, Marbet GA, Duckert F. Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemostas 1980; 44: 87-91
  • 11 Weber K, Osborn M. The reliability of molecular weight determinations by dodecylsulfate polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
  • 12 Scheidegger JJ. Une micro-methode de l’électrophorèse. Int Arch Allerg 1955; 7: 103
  • 13 Kurachi K, Schmer G, Hermodson MA, Teller DC, Davie EW. Characterization of human, bovine and horse antithrombin. Biochemistry 1976; 15: 368-372
  • 14 Franza BR, Aronson DL, Finlayson JS. Activation of human prothrombin by a procaogulant fraction from the venom of Echis carinatus Identification of a high molecular weight intermediate with thrombin activity. J Biol Chem 1975; 250: 7057-7068
  • 15 Lundblad RL, Kingdon HS, Mann KG. Thrombin. Meth Enzymol 1976; 45: 156-177
  • 16 Fenton JW II, Fasco MJ, Stackrow AB, Aronson DL, Young AM, Finlayson JS. Human thrombins Production, evaluation and properties of α-thrombin. J Biol Chem 1977; 252: 3587-3598
  • 17 Tran TH, Duckert F. Heparin cofactor II determination Levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation. Thromb Haemostas 1984; 52: 112-116
  • 18 Tran TH, Zbinden B, Lammle B, Duckert F. Methodology and clinical significance of heparin cofactor II (HCII). Sem Thromb Haemostas 1985; 11: 342-346
  • 19 Tran TH, Marbet GA, Duckert F. Rabbit antibodies against the procoagulant activity (VIII :C) of human factor VIII. Some theoretical and practical considerations on the human factor VIII molecule using heterologous antibodies. Thromb Haemostas 1981; 46: 699-705
  • 20 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
  • 21 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-2225
  • 22 Friberger P, Egberg N, Holmer E, Hellgren M, Blomback M. Antithrombin assay - the use of human or bovine thrombin and the observation of a “second” heparin cofactor. Thromb Res 1982; 25: 433-436
  • 23 Tran TH, Marbet GA, Duckert F. Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; 2: 413-414